Buffalo, NY (PRWEB) March 8, 2007
Empire Genomics, LLC (EG) announced that it has formed a strategic alliance with BioDiscovery, Inc (BD) to offer complete solutions to customers in the array comparative genomic hybridization field. Empire's best in class aCGH services and products will be combined with BioDiscovery's industry leading proprietary software to reduce the difficulty in obtaining high quality data from assays. EG and BDI will optimize their products to ensure consistency from assay to assay and researcher to researcher. Further EG and BDI will work to continually develop and bring new and innovative products to market. Also as a part of this alliance Empire Genomics and BioDiscovery will co-market and co-promote their products and services to end users.
"This alliance with BioDiscovery is part of our core strategy to work to bring the best solutions to our Empire customers. While we possess the best in aCGH kits and services it is crucial to have a software offering that is just as great and user friendly; in BioDiscovery we have that!" commented Anthony Johnson, CEO of Empire Genomics. "As we continue to bring novel technologies and diagnostic products to market, reducing variability and ensuring that our customers can consistently get desired results from their experiments are of a paramount importance to our business model. I am thoroughly pleased to work with BioDiscovery and truly excited about our future."
"We are very excited about working with Empire Genomics in providing a high quality complete solution to our mutual customers. Having worked with EG array images, we know that they are of high quality and combining those with BioDiscovery's leading image and aCGH analysis software ImaGene CGH provides a truly best-in-class solution," said Dr. Soheil Shams, President of BioDiscovery. "We look forward to expanding our collaboration with Empire Genomics and continuing to provide innovative software solutions for CGH research."
About Empire Genomics, LLC
Empire Genomics LLC of Buffalo, New York, is a new firm in the field of molecular karyotyping technology founded on the expertise of Roswell Park Cancer Institute researcher, Dr. Norma Nowak. It offers a wide range of best in class products and services on its proprietary array-based comparative genomics platform technology that are used to quantify changes in chromosomal abnormalities. Empire possesses extensive experience in the areas of cancer research as well as developmental disorders. The firm services the global genetic research and molecular diagnostic markets and is leveraging its technology to marshal in the exciting new era of personalized medicine. It offers extremely high quality, high throughput and cost effective genomic analysis results.
About BioDiscovery, Inc.
Founded in 1997 in Los Angeles, BioDiscovery is a leader in the development of microarray bioinformatics software and services. BioDiscovery develops and sells advanced software solutions and services that enable its customers to revolutionize drug discovery and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray technology. BioDiscovery provides a full line of modular software packages spanning the entire microarray process, including enterprise data management, image processing, data mining, statistical analysis and collaborative knowledge management.